AADR vs CNCR

Both AADR and CNCR are ETFs. AADR has a higher 5-year return than CNCR (10.06% vs 5.23%). AADR has a higher expense ratio than CNCR (1.1% vs 0.79%). Below is the comparison between AADR and CNCR.

AADR CNCR
Security Type ETF ETF
Segment Equity: Global Ex-U.S. - Total Market Growth Equity: U.S. Biotech
Family AdvisorShares Exchange Traded Concepts
Net Assets $79.80M $42.60M
Expense Ratio 1.10% 0.79%
Management Style passive (index-based) passive (index-based)
Dividend Yield 0.31% 0.90%
Underlying Index -- Loncar Cancer Immunotherapy Index
YTD Return 8.46% -9.39%
1-Year Return 17.51% 4.83%
3-Year Return 10.92% 12.22%
5-Year Return 10.06% 5.23%
10-Year Return 9.70% 0.00%

AADR description

The Fund seeks long-term capital appreciation above international benchmarks such as the MSCI EAFE Index and the BNY Mellon Classic ADR Index. The Fund selects a portfolio of U.S. traded securities of non-U.S. organizations, most often American Depositary Receipts (ADRs), included in the BNY Mellon Classic ADR Index.

AADR performance & returns

YTD Return 8.46%
1-Month Return 1.00%
3-Month Return 0.27%
1-Year Return 17.51%
3-Year Return 10.92%
5-Year Return 10.06%
10-Year Return 9.70%
AADR expense ratio is 1.1%.

AADR holdings

Top 10 Holdings (45.63% of Total Assets)

Name Symbol % Assets
MercadoLibre Inc MELI.SA 7.21%
NICE Ltd ADR NICE 6.54%
Gold Fields Ltd ADR GFI.JO 5.86%
argenx SE ADR ARGX 5.52%
Anglogold Ashanti Ltd ADR AU.JO 3.64%
TAL Education Group ADR TAL 3.63%
ASML Holding NV ADR ASML 3.59%
ZTO Express (Cayman) Inc ADR ZTO 3.35%
Sibanye Stillwater Ltd ADR SBSW.JO 3.21%
LVMH Moet Hennessy Louis Vuitton SE ADR LVMUY.PA 3.08%

Other relevant AADR comparisons

You may also want to check out the following AADR comparisons that investors often look for on Finny

    Or use Finny Compare Wizard to create a comparison you’d like to see.

    CNCR description

    The Fund seeks to track the total return performance of the Loncar Cancer Immunotherapy Index. The Index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies having a high strategic focus on the development of drugs that harness the bodys own immune system to fight cancer.

    CNCR performance & returns

    YTD Return -9.39%
    1-Month Return -8.33%
    3-Month Return -6.27%
    1-Year Return 4.83%
    3-Year Return 12.22%
    5-Year Return 5.23%
    10-Year Return 0.00%
    CNCR expense ratio is 0.79%.

    CNCR holdings

    Top 10 Holdings (47.22% of Total Assets)

    Name Symbol % Assets
    Replimune Group Inc REPL 6.36%
    BeiGene Ltd ADR BGNE 5.68%
    BioNTech SE ADR BNTX.DE 5.51%
    Trillium Therapeutics Inc TRIL.TO 5.20%
    CRISPR Therapeutics AG CRSP 4.82%
    Fate Therapeutics Inc FATE 4.66%
    Xencor Inc XNCR 4.12%
    Iovance Biotherapeutics Inc IOVA 3.78%
    Zymeworks Inc Registered Shs When Issued ZYME.TO 3.56%
    argenx SE ADR ARGX 3.53%

    Other relevant CNCR comparisons

    You may also want to check out the following CNCR comparisons that investors often look for on Finny

    Or use Finny Compare Wizard to create a comparison you’d like to see.

    You can check out all comparisons Finny users have looked for here. Feel free to the browse the list and view the comparisons that are of an interest to you.